These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 39047427)

  • 1. Enhanced CFTR modulator efficacy in ΔF508 CFTR mouse organoids by ablation of RFFL ubiquitin ligase.
    Hinata D; Fukuda R; Ishiguro H; Kamada Y; Okiyoneda T
    Biochem Biophys Res Commun; 2024 Jul; 733():150433. PubMed ID: 39047427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor.
    Reasoner SA; Bernard R; Waalkes A; Penewit K; Lewis J; Sokolow AG; Brown RF; Edwards KM; Salipante SJ; Hadjifrangiskou M; Nicholson MR
    mBio; 2024 Feb; 15(2):e0193523. PubMed ID: 38275294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Ubiquitin Ligase RNF34 Participates in the Peripheral Quality Control of CFTR (RNF34 Role in CFTR PeriQC).
    Taniguchi S; Ito Y; Kiritani H; Maruo A; Sakai R; Ono Y; Fukuda R; Okiyoneda T
    Front Mol Biosci; 2022; 9():840649. PubMed ID: 35355508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of elexacaftor/tezacaftor/ivacaftor on bacterial cultures from people with cystic fibrosis.
    Beck MR; Hornick DB; Pena TA; Singh SB; Wright BA
    Pediatr Pulmonol; 2023 May; 58(5):1569-1573. PubMed ID: 36807558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of α-Tocopherol succinate as an RFFL-substrate interaction inhibitor inducing peripheral CFTR stabilization and apoptosis.
    Taniguchi S; Ono Y; Doi Y; Taniguchi S; Matsuura Y; Iwasaki A; Hirata N; Fukuda R; Inoue K; Yamaguchi M; Tashiro A; Egami D; Aoki S; Kondoh Y; Honda K; Osada H; Kumeta H; Saio T; Okiyoneda T
    Biochem Pharmacol; 2023 Sep; 215():115730. PubMed ID: 37543348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chaperone-Independent Peripheral Quality Control of CFTR by RFFL E3 Ligase.
    Okiyoneda T; Veit G; Sakai R; Aki M; Fujihara T; Higashi M; Susuki-Miyata S; Miyata M; Fukuda N; Yoshida A; Xu H; Apaja PM; Lukacs GL
    Dev Cell; 2018 Mar; 44(6):694-708.e7. PubMed ID: 29503157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two
    Graeber SY; Vitzthum C; Pallenberg ST; Naehrlich L; Stahl M; Rohrbach A; Drescher M; Minso R; Ringshausen FC; Rueckes-Nilges C; Klajda J; Berges J; Yu Y; Scheuermann H; Hirtz S; Sommerburg O; Dittrich AM; Tümmler B; Mall MA
    Am J Respir Crit Care Med; 2022 Mar; 205(5):540-549. PubMed ID: 34936849
    [No Abstract]   [Full Text] [Related]  

  • 8. Ligand-based virtual-screening identified a novel CFTR ligand which improves the defective cell surface expression of misfolded ABC transporters.
    Taniguchi S; Berenger F; Doi Y; Mimura A; Yamanishi Y; Okiyoneda T
    Front Pharmacol; 2024; 15():1370676. PubMed ID: 38666024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosis.
    Marshall LZ; Espinosa R; Starner CI; Gleason PP
    J Manag Care Spec Pharm; 2023 Jun; 29(6):599-606. PubMed ID: 37276039
    [No Abstract]   [Full Text] [Related]  

  • 10. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Healthcare Resource Utilization and Associated Costs Among People With Cystic Fibrosis in the US: A Retrospective Claims Analysis.
    Schechter MS; Sabater-Anaya N; Oster G; Weycker D; Wu H; Arteaga-Solis E; Bagal S; McGarry LJ; Van Brunt K; Geiger JM
    Pulm Ther; 2023 Dec; 9(4):479-498. PubMed ID: 37874528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One
    Wainwright C; McColley SA; McNally P; Powers M; Ratjen F; Rayment JH; Retsch-Bogart G; Roesch E; Ahluwalia N; Chin A; Chu C; Lu M; Menon P; Waltz D; Weinstock T; Zelazoski L; Davies JC
    Am J Respir Crit Care Med; 2023 Jul; 208(1):68-78. PubMed ID: 37154609
    [No Abstract]   [Full Text] [Related]  

  • 12. In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis.
    Bihler H; Sivachenko A; Millen L; Bhatt P; Patel AT; Chin J; Bailey V; Musisi I; LaPan A; Allaire NE; Conte J; Simon NR; Magaret AS; Raraigh KS; Cutting GR; Skach WR; Bridges RJ; Thomas PJ; Mense M
    J Cyst Fibros; 2024 Jul; 23(4):664-675. PubMed ID: 38388235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two
    Graeber SY; Renz DM; Stahl M; Pallenberg ST; Sommerburg O; Naehrlich L; Berges J; Dohna M; Ringshausen FC; Doellinger F; Vitzthum C; Röhmel J; Allomba C; Hämmerling S; Barth S; Rückes-Nilges C; Wielpütz MO; Hansen G; Vogel-Claussen J; Tümmler B; Mall MA; Dittrich AM
    Am J Respir Crit Care Med; 2022 Aug; 206(3):311-320. PubMed ID: 35536314
    [No Abstract]   [Full Text] [Related]  

  • 14. Theratyping of the Rare CFTR Variants E193K and R334W in Rectal Organoid-Derived Epithelial Monolayers.
    Ciciriello F; Bijvelds MJC; Alghisi F; Meijsen KF; Cristiani L; Sorio C; Melotti P; Fiocchi AG; Lucidi V; De Jonge HR
    J Pers Med; 2022 Apr; 12(4):. PubMed ID: 35455747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for
    Mall MA; Brugha R; Gartner S; Legg J; Moeller A; Mondejar-Lopez P; Prais D; Pressler T; Ratjen F; Reix P; Robinson PD; Selvadurai H; Stehling F; Ahluwalia N; Arteaga-Solis E; Bruinsma BG; Jennings M; Moskowitz SM; Noel S; Tian S; Weinstock TG; Wu P; Wainwright CE; Davies JC
    Am J Respir Crit Care Med; 2022 Dec; 206(11):1361-1369. PubMed ID: 35816621
    [No Abstract]   [Full Text] [Related]  

  • 16. Response to elexacaftor/tezacaftor/ivacaftor in intestinal organoids derived from people with cystic fibrosis.
    Furstova E; Dousova T; Beranek J; Libik M; Fila L; Modrak M; Cinek O; Macek M; Drevinek P
    J Cyst Fibros; 2022 Mar; 21(2):243-245. PubMed ID: 34348870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in an adolescent with homozygous G85E cystic fibrosis.
    Stekolchik E; Saul D; Chidekel A
    Respir Med Case Rep; 2022; 40():101775. PubMed ID: 36411821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real world outcomes of CFTR modulator therapy in Australian adults and children.
    Kuek S; McCullagh A; Paul E; Armstrong D
    Pulm Pharmacol Ther; 2023 Oct; 82():102247. PubMed ID: 37574040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor-Ivacaftor.
    Tümmler B
    Front Pharmacol; 2023; 14():1158207. PubMed ID: 37025483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal Profiling of the Intestinal Microbiome in Children with Cystic Fibrosis Treated with Elexacaftor-Tezacaftor-Ivacaftor.
    Reasoner SA; Bernard R; Waalkes A; Penewit K; Lewis J; Sokolow AG; Brown RF; Edwards KM; Salipante SJ; Hadjifrangiskou M; Nicholson MR
    medRxiv; 2023 Nov; ():. PubMed ID: 37645804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.